🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Roughly 90% of drug candidates fail. It can cost $2.6B and over a decade to bring one to market. We need strong incentives—price control imports from Europe will kill them. forbes.com/sites/sallypip…

Celebrate the centennial of William F. Buckley Jr. with an unforgettable day in Newport Beach—sailing on the tall ship America and dinner with thinkers who knew him best. Join Pacific Research Institute Oct. 4! pacificresearch.org/events/william…

Forget long waits and insurance hurdles. Drugmakers are teaming up with telehealth to bring GLP-1s like Wegovy and Zepbound straight to patients. It’s a game-changer for public health. forbes.com/sites/sallypip…

Trump’s Most Favored Nation drug plan? It’s price controls dressed up as patriotism. It won’t stop foreign freeloading—it’ll just punish American patients by slowing the next generation of life-saving cures. newsmax.com/sallypipes/pat…

"A recent executive order from the Trump administration directs the government to implement policies that will lead to U.S. drug prices being pegged to the lower drug prices available in other developed countries," writes PRI's @SallyPipes. pacificresearch.org/dont-take-cutt…

A night to honor free minds and fearless journalism—Mark Q. Cunningham of the @NYPost takes the spotlight Pacific Research Institute’s inaugural Milton Friedman Dinner on June 25 at the Union Club. pacificresearch.org/events/pacific…

Linking U.S. drug prices to Europe or Canada won’t just slow innovation—it could kill it. Fewer new medicines means more suffering, longer waits, and lost hope for millions. forbes.com/sites/sallypip…

We shouldn’t fight foreign freeloading by importing drug price controls. Trump’s revived Most Favored Nation plan risks rationing care, crushing research, and introducing significant complications to a thriving domestic industry. newsmax.com/sallypipes/pat…

Medicaid should help pregnant women, the disabled, and kids—not fund bloated programs through financial trickery. CMS is right to refocus the program. washingtonexaminer.com/restoring-amer…

Let’s negotiate fairer drug prices internationally by holding countries accountable for respecting U.S. intellectual property. Trade policy should protect American innovation, not punish it. Pacific Research Institute pacificresearch.org/to-improve-dru…

It’s simple: if you’re a healthy adult with no kids, you should work, study, or volunteer to qualify for Medicaid. House Republicans agree — and that commonsense reform would save $301 billion over 7 years. washingtonexaminer.com/restoring-amer…

Americans are at a high risk for skin cancer — partly because our sunscreen is stuck in the 1990s. The FDA’s supposedly “safer” procedure for bringing new sunscreens to market is keeping effective products from our shelves. Time to fix this. statnews.com/2025/05/20/fda…

Californians use 34% less energy than the national average—yet pay 56% more. Why? Green energy mandates. Read Pacific Research Institute’s study on how state policies are driving up your bills. pacificresearch.org/new-study-reve…

Want to lower drug prices? Start with the middlemen. Pharmacy benefit managers and others take up to half of every dollar spent on prescriptions. Reign them in—don’t punish innovation. forbes.com/sites/sallypip…

Join the celebration of a century. On Oct. 4, Pacific Research Institute will honor the life and legacy of William F. Buckley Jr. with sailing, cocktails, and conversation in scenic Newport Beach. pacificresearch.org/events/william…

Decades of evidence from Canada—my native land—illustrate that single-payer offers a one-way ticket to healthcare ruin. Long waits, restrictions on access to cutting-edge treatments, and unnecessary suffering are endemic to single-payer. newsmax.com/sallypipes/sin…

Direct-to-consumer GLP-1 sales put patients first: no insurance roadblocks, no sketchy compounding pharmacies—just effective, FDA-approved treatments from the source for less than the list price. That’s a win-win. forbes.com/sites/sallypip…

States have long used shady “provider taxes” to game Medicaid and grab more from federal taxpayers. Now CMS is cracking down—and it’s about time. washingtonexaminer.com/restoring-amer…

Price controls abroad don’t even cover the $2.9B it takes to develop a new drug. Copying their model would wreck U.S. innovation. Instead, let’s fix our broken payment system — especially PBMs and 340B. More from Pacific Research Institute here: pacificresearch.org/to-improve-dru…

1 in 5 Americans will get skin cancer by the time they turn 70. But regulators still block access to better sunscreens proven safe in Europe and Asia. This isn’t safety — it’s outdated bureaucracy that’s putting lives at risk. statnews.com/2025/05/20/fda…